Richard S. Geary

14.2k total citations · 8 hit papers
168 papers, 10.7k citations indexed

About

Richard S. Geary is a scholar working on Molecular Biology, Surgery and Cardiology and Cardiovascular Medicine. According to data from OpenAlex, Richard S. Geary has authored 168 papers receiving a total of 10.7k indexed citations (citations by other indexed papers that have themselves been cited), including 96 papers in Molecular Biology, 23 papers in Surgery and 23 papers in Cardiology and Cardiovascular Medicine. Recurrent topics in Richard S. Geary's work include DNA and Nucleic Acid Chemistry (44 papers), RNA Interference and Gene Delivery (36 papers) and Advanced biosensing and bioanalysis techniques (30 papers). Richard S. Geary is often cited by papers focused on DNA and Nucleic Acid Chemistry (44 papers), RNA Interference and Gene Delivery (36 papers) and Advanced biosensing and bioanalysis techniques (30 papers). Richard S. Geary collaborates with scholars based in United States, Canada and Netherlands. Richard S. Geary's co-authors include Rosie Z. Yu, Brenda F. Baker, Arthur A. Levin, Joseph L. Witztum, C. Frank Bennett, Steven G. Hughes, Rosanne M. Crooke, Stanley T. Crooke, Sotirios Tsimikas and Mark J. Graham and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Circulation.

In The Last Decade

Richard S. Geary

162 papers receiving 10.4k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Pharmacokinetics, biodistribution and cell uptake of antisense oligonucleotides

2015 647 citations Richard S. Geary, Rosie Z. Yu et al. profile →
Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials

2016 544 citations Richard S. Geary, Shuting Xia et al. profile →
Cardiovascular and Metabolic Effects of ANGPTL3 Antisense Oligonucleotides

2017 454 citations Bruce L. Tai, Rosie Z. Yu et al. profile →
Volanesorsen and Triglyceride Levels in Familial Chylomicronemia Syndrome

2019 416 citations Joseph L. Witztum, Daniel Gaudet et al. profile →
Antisense Inhibition of Apolipoprotein C-III in Patients with Hypertriglyceridemia

2015 409 citations Daniel Gaudet, Veronica J. Alexander et al. profile →
Targeting APOC3 in the Familial Chylomicronemia Syndrome

2014 381 citations Daniel Gaudet, Veronica J. Alexander et al. profile →
Antisense therapy targeting apolipoprotein(a): a randomised, double-blind, placebo-controlled phase 1 study

2015 358 citations Sotirios Tsimikas, Steven G. Hughes et al. profile →
Apolipoprotein C-III reduction in subjects with moderate hypertriglyceridaemia and at high cardiovascular risk

2021 146 citations Ewa Karwatowska‐Prokopczuk, Seth J. Baum et al. European Heart Journal profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Richard S. Geary United States	59	6.1k	2.6k	2.4k	1.9k	1.7k	168	10.7k
Brenda F. Baker United States	45	4.8k 0.8×	2.0k 0.8×	1.6k 0.7×	1.4k 0.7×	1.5k 0.9×	86	8.6k
Rosie Z. Yu United States	39	3.2k 0.5×	1.4k 0.5×	1.0k 0.4×	789 0.4×	837 0.5×	69	5.7k
Nan Wang United States	52	5.6k 0.9×	8.0k 3.0×	912 0.4×	2.0k 1.1×	2.3k 1.4×	91	12.4k
Philippe G. Frank United States	46	4.7k 0.8×	1.3k 0.5×	816 0.3×	473 0.3×	2.8k 1.6×	81	7.9k
Ronit Simantov United States	36	5.5k 0.9×	782 0.3×	632 0.3×	309 0.2×	2.6k 1.6×	88	11.2k
Nam Jin Yoo South Korea	59	8.1k 1.3×	1.2k 0.5×	638 0.3×	193 0.1×	2.7k 1.6×	298	12.6k
R W Milne Canada	39	2.0k 0.3×	2.2k 0.8×	1000 0.4×	1.9k 1.0×	990 0.6×	64	5.0k
G. Steven Bova United States	52	7.9k 1.3×	1.2k 0.5×	212 0.1×	693 0.4×	2.9k 1.7×	132	12.6k
Peter Olson United States	31	4.4k 0.7×	987 0.4×	292 0.1×	336 0.2×	1.9k 1.1×	86	8.3k
Dick J. Richel Netherlands	43	3.5k 0.6×	1.6k 0.6×	662 0.3×	118 0.1×	2.2k 1.3×	107	9.6k

Countries citing papers authored by Richard S. Geary

Since Specialization

Citations

This map shows the geographic impact of Richard S. Geary's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Richard S. Geary with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Richard S. Geary more than expected).

Fields of papers citing papers by Richard S. Geary

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Richard S. Geary. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Richard S. Geary. The network helps show where Richard S. Geary may publish in the future.

Co-authorship network of co-authors of Richard S. Geary

This figure shows the co-authorship network connecting the top 25 collaborators of Richard S. Geary. A scholar is included among the top collaborators of Richard S. Geary based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Richard S. Geary. Richard S. Geary is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Hladunewich, Michelle, Michael L. McCaleb, Richard A. Robson, et al.. (2025). A single-arm phase 2 trial of an investigational RNA therapeutic to complement factor B sefaxersen for treatment of IgA nephropathy. Kidney International. 109(3). 592–601.

Baker, Brenda F., Shuting Xia, Jeffery A. Engelhardt, et al.. (2024). Safety and Tolerability of GalNAc ₃ -Conjugated Antisense Drugs Compared to the Same-Sequence 2′- O -Methoxyethyl-Modified Antisense Drugs: Results from an Integrated Assessment of Phase 1 Clinical Trial Data. Nucleic Acid Therapeutics. 34(1). 18–25. 4 indexed citations

Barbour, Sean, Michelle Hladunewich, Angela Makris, et al.. (2022). An Exploratory Trial of an Investigational RNA Therapeutic, IONIS-FB-LRx, for Treatment of IgA Nephropathy. Journal of the American Society of Nephrology. 33(11S). 800–800. 4 indexed citations

Baker, Brenda F., Shuting Xia, T. Jesse Kwoh, et al.. (2022). Integrated Assessment of Phase 2 Data on GalNAc ₃ -Conjugated 2′- O -Methoxyethyl-Modified Antisense Oligonucleotides. Nucleic Acid Therapeutics. 33(1). 72–80. 11 indexed citations

Yu, Rosie Z., et al.. (2021). Interspecies Scaling of Human Clearance and Plasma Trough Exposure for Antisense Oligonucleotides: A Retrospective Analysis of GalNAc3-Conjugated and Unconjugated-Antisense Oligonucleotides. Nucleic Acid Therapeutics. 31(4). 298–308. 11 indexed citations

Xia, Shuting, et al.. (2021). Improvements in the Tolerability Profile of 2′- O -Methoxyethyl Chimeric Antisense Oligonucleotides in Parallel with Advances in Design, Screening, and Other Methods. Nucleic Acid Therapeutics. 31(6). 417–426. 8 indexed citations

Willmann, Stefan, Alexander Solms, Markus Jensen, et al.. (2021). PK/PD modeling of FXI antisense oligonucleotides to bridge the dose‐FXI activity relation from healthy volunteers to end‐stage renal disease patients. CPT Pharmacometrics & Systems Pharmacology. 10(8). 890–901. 36 indexed citations

Boyer, David S., Jayashree Sahni, Sascha Fauser, et al.. (2021). Systemic Antisense Oligonucleotide Inhibition of Complement Factor B for Treatment of Geographic Atrophy: Results of a Placebo-controlled Phase 1 Dose-Escalation Study. Investigative Ophthalmology & Visual Science. 62(8). 196–196. 1 indexed citations

Watts, Lynnetta M., Ewa Karwatowska‐Prokopczuk, Eunju Hurh, et al.. (2020). Treatment with Volanesorsen, a 2′-O-Methoxyethyl-Modified Antisense Oligonucleotide Targeting APOC3 mRNA, Does Not Affect the QTc Interval in Healthy Volunteers. Nucleic Acid Therapeutics. 30(4). 198–206. 3 indexed citations

10.

Gaudet, Daniel, Ewa Karwatowska‐Prokopczuk, Seth J. Baum, et al.. (2020). Vupanorsen, an N-acetyl galactosamine-conjugated antisense drug to ANGPTL3 mRNA, lowers triglycerides and atherogenic lipoproteins in patients with diabetes, hepatic steatosis, and hypertriglyceridaemia. European Heart Journal. 41(40). 3936–3945. 196 indexed citations

11.

Jaffe, Glenn J., Jayashree Sahni, Sascha Fauser, et al.. (2020). Development of IONIS-FB-LRx to Treat Geographic Atrophy Associated with AMD. Investigative Ophthalmology & Visual Science. 61(7). 4305–4305. 23 indexed citations

12.

Morgan, Erin, Bruce L. Tai, Nguyen C. Pham, et al.. (2019). Antisense Inhibition of Glucagon Receptor by IONIS-GCGRRx Improves Type 2 Diabetes Without Increase in Hepatic Glycogen Content in Patients With Type 2 Diabetes on Stable Metformin Therapy. Diabetes Care. 42(4). 585–593. 42 indexed citations

13.

Crooke, Stanley T., Brenda F. Baker, Nguyen C. Pham, et al.. (2017). The Effects of 2′- O -Methoxyethyl Oligonucleotides on Renal Function in Humans. Nucleic Acid Therapeutics. 28(1). 10–22. 53 indexed citations

14.

Bethune, Claudette, et al.. (2017). Pharmacokinetics and Pharmacodynamics of Ionis-FXIRx, an Antisense Inhibitor of Factor XI, in Patients with End-Stage Renal Disease on Hemodialysis. Blood. 130. 1116–1116. 18 indexed citations

15.

McCaleb, Michael L., Tamar R. Grossman, Peter Adamson, et al.. (2017). Systemic Pharmacodynamic Efficacy of a Complement Factor B Antisense Oligonucleotide in Preclinical and Phase 1 Clinical Studies. Investigative Ophthalmology & Visual Science. 58(8). 1952–1952. 5 indexed citations

16.

Geary, Richard S., John Matson, Megan Pearce, et al.. (2009). Effect of dose and plasma concentration on liver uptake and pharmacologic activity of a 2′-methoxyethyl modified chimeric antisense oligonucleotide targeting PTEN. Biochemical Pharmacology. 78(3). 284–291. 66 indexed citations

17.

Yu, Rosie Z., et al.. (2008). Lack of Pharmacokinetic Interaction of Mipomersen Sodium (ISIS 301012), a 2′-O-Methoxyethyl Modified Antisense Oligonucleotide Targeting Apolipoprotein B-100 Messenger RNA, with Simvastatin and Ezetimibe. Clinical Pharmacokinetics. 48(1). 39–50. 82 indexed citations

18.

Raoof, Araz, et al.. (2002). Effect of sodium caprate on the intestinal absorption of two modified antisense oligonucleotides in pigs. European Journal of Pharmaceutical Sciences. 17(3). 131–138. 52 indexed citations

19.

Ray, Kausik K., et al.. (1996). INTRACEREBRAL HAEMORRHAGE IN A YOUNG ADULT: CONSIDER AMPHETAMINE ABUSE. International Journal of Clinical Practice. 50(2). 115–116. 8 indexed citations

20.

Weiss, Douglas J., Richard S. Geary, Thomas J. Bucci, et al.. (1994). The comparative metabolism of diisopropyl methylphosphonate in mink and rats. Archives of Environmental Contamination and Toxicology. 27(3). 420–5. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact